Erin Flynt
Overview
Explore the profile of Erin Flynt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amatangelo M, Flynt E, Stong N, Ray P, Van Oekelen O, Wang M, et al.
Cell Rep Med
. 2024 May;
5(6):101571.
PMID: 38776914
Iberdomide is a next-generation cereblon (CRBN)-modulating agent in the clinical development in multiple myeloma (MM). The analysis of biomarker samples from relapsed/refractory patients enrolled in CC-220-MM-001 (ClinicalTrials.gov: NCT02773030), a phase...
2.
Van Oekelen O, Amatangelo M, Guo M, Upadhyaya B, Cribbs A, Kelly G, et al.
Cell Rep Med
. 2024 May;
5(6):101584.
PMID: 38776911
Iberdomide is a potent cereblon E3 ligase modulator (CELMoD agent) with promising efficacy and safety as a monotherapy or in combination with other therapies in patients with relapsed/refractory multiple myeloma...
3.
Neri P, Barwick B, Jung D, Patton J, Maity R, Tagoug I, et al.
Blood Cancer Discov
. 2023 Nov;
5(1):56-73.
PMID: 37934799
Significance: We show that IKZF1-bound enhancers are critical for IMiD efficacy and that the factor ETV4 can bind the same enhancers and substitute for IKZF1 and mediate IMiD resistance by...
4.
Ansari-Pour N, Samur M, Flynt E, Gooding S, Towfic F, Stong N, et al.
Blood
. 2022 Oct;
141(6):620-633.
PMID: 36223594
Large-scale analyses of genomic data from patients with newly diagnosed multiple myeloma (ndMM) have been undertaken, however, large-scale analysis of relapsed/refractory MM (rrMM) has not been performed. We hypothesize that...
5.
Stong N, Ortiz-Estevez M, Towfic F, Samur M, Agarwal A, Corre J, et al.
Blood
. 2022 Aug;
141(13):1574-1583.
PMID: 35984902
Although translocation events between chromosome 4 (NSD2 gene) and chromosome 14 (immunoglobulin heavy chain [IgH] locus) (t(4;14)) is considered high risk in newly diagnosed multiple myeloma (NDMM), only ∼30% to...
6.
Gooding S, Ansari-Pour N, Kazeroun M, Karagoz K, Polonskaia A, Salazar M, et al.
Blood
. 2022 Jul;
140(16):1816-1821.
PMID: 35853156
The acquisition of a multidrug refractory state is a major cause of mortality in myeloma. Myeloma drugs that target the cereblon (CRBN) protein include widely used immunomodulatory drugs (IMiDs), and...
7.
Sudha P, Ahsan A, Ashby C, Kausar T, Khera A, Kazeroun M, et al.
Clin Cancer Res
. 2022 May;
28(13):2854-2864.
PMID: 35522533
Purpose: We designed a comprehensive multiple myeloma targeted sequencing panel to identify common genomic abnormalities in a single assay and validated it against known standards. Experimental Design: The panel comprised...
8.
Karagoz K, Stokes M, Ortiz-Estevez M, Towfic F, Flynt E, Gooding S, et al.
Front Genet
. 2022 Feb;
13:831779.
PMID: 35222546
Immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide, are used in the routine treatment for multiple myeloma (MM) patients. Cereblon (CRBN) is the direct molecular target of IMiDs. While CRBN is...
9.
Ortiz-Estevez M, Towfic F, Flynt E, Stong N, Jang I, Wang K, et al.
BMC Med Genomics
. 2021 Dec;
14(1):295.
PMID: 34922559
Background: Despite significant therapeutic advances in improving lives of multiple myeloma (MM) patients, it remains mostly incurable, with patients ultimately becoming refractory to therapies. MM is a genetically heterogeneous disease...
10.
Thakurta A, Pierceall W, Amatangelo M, Flynt E, Agarwal A
Oncotarget
. 2021 Jul;
12(15):1555-1563.
PMID: 34316334
Multiple Myeloma (MM) is an incurable malignancy with current treatment choices primarily comprising combination regimens implemented with a risk-adapted approach. Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs) lenalidomide (LEN) and pomalidomide (POM)...